Search Results

Floseal Hemostatic Matrix

Floseal is an effective adjunct hemostatic agent proven in a wide-range of bleeding scenarios1 with a proprietary combination of two independent hemostatic agents.1, 2

OLD Our History

​Innovation is at our core.  For nearly a century, we’ve been focused on saving and sustaining lives and elevating patient care.

Baxter Reports Fourth-Quarter and Full-Year 2023 Results

Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2023, and provided its financial guidance for full-year and first-quarter 2024. 

Baxter Reports Second-Quarter 2023 Results

Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the second quarter of 2023.

Baxter Launches PERCLOT Absorbable Hemostatic Powder

Baxter International Inc. (NYSE:BAX), a global leader in advancing surgical innovation, today announced the launch of PERCLOT Absorbable Hemostatic Powder in the U.S. PERCLOT is a passive, absorbable hemostatic powder that is ready to use and designed for patients with intact coagulation to address mild bleeding.1 

Baxter Reports First-Quarter 2023 Results

Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2023.

Baxter Showcases Surgical Innovations at AORN Global Surgical Conference and Expo 2023

Baxter International Inc. (NYSE:BAX), a leader in solutions to advance surgical innovation, unveiled multiple new additions to its surgical portfolios at the Association of periOperative Registered Nurses (AORN) Global Surgical Conference & Expo 2023, taking place April 1 through April 4, 2023.

Baxter Reports Fourth-Quarter and Full-Year 2021 Results

Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2021, and provided its financial guidance for full-year and first-quarter 2022. Fourth-quarter and full-year 2021 results reflect 19 days of contribution from Hillrom Holdings, Inc. (Hillrom) subsequent to Baxter’s acquisition of the company on Dec. 13, 2021.

Baxter Completes Acquisition of Hillrom, Creating ~$15 Billion Global Medtech Leader

Baxter International Inc. (NYSE:BAX), a global medtech leader, announced today it has completed its acquisition of Hillrom. Baxter paid $156.00 in cash for each outstanding share of Hillrom common stock for a purchase price of $10.5 billion (based on Hillrom share counts at closing). Including the assumption of Hillrom's outstanding debt obligations, the enterprise value of the transaction is approximately $12.5 billion.

Baxter Reports Third-Quarter 2021 Results

Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the third quarter of 2021.